中国医学前沿杂志（电子版）
中國醫學前沿雜誌（電子版）
중국의학전연잡지（전자판）
CHINESE JOURNAL OF THE FRONTIERS OF MEDICAL SCIENCE(ELECTRONIC VERSION)
2013年
7期
26-28
,共3页
吴豫梅%林霖%石峰%蔺金华
吳豫梅%林霖%石峰%藺金華
오예매%림림%석봉%린금화
吡格列酮%2型糖尿病%冠心病%动脉粥样硬化%相关危险因素
吡格列酮%2型糖尿病%冠心病%動脈粥樣硬化%相關危險因素
필격렬동%2형당뇨병%관심병%동맥죽양경화%상관위험인소
Pioglitazone%Type 2 diabetes%Coronary heart disease%Atherosclerosis%Related risk factors
目的探讨吡格列酮治疗2型糖尿病合并冠心病患者对其动脉粥样硬化相关危险因素及预后的影响。方法选取2010年8月至2012年1月在本院进行治疗的2型糖尿病合并冠心病患者202例，随机分为治疗组和对照组，两组均给予常规治疗；在此基础上，治疗组（101例）加用吡格列酮（15 mg/次，1次/天）治疗，期间定期随访，1年后比较2组血液动脉粥样硬化相关危险因素及心血管不良事件发生率。结果治疗组血清PAI-1（纤溶酶原激活物抑制物-1）水平为（4.15±0.47）ng/ml，P-选择素水平为（12.38±3.56）ng/ml，对照组血清PAI-1水平为（7.46±1.73）ng/ml，P-选择素水平为（15.84±6.32）ng/ml，两组比较差异显著（P＜0.05）；治疗组空腹血糖、餐后血糖、空腹胰岛素、糖化血红蛋白水平和胰岛素抵抗指数及急性冠脉综合征、不稳定性心绞痛和靶血管重建发生率显著低于对照组，（P＜0.05）。结论吡格列酮用于治疗2型糖尿病合并冠心病，能降低其动脉粥样硬化相关危险因素从而改善预后。
目的探討吡格列酮治療2型糖尿病閤併冠心病患者對其動脈粥樣硬化相關危險因素及預後的影響。方法選取2010年8月至2012年1月在本院進行治療的2型糖尿病閤併冠心病患者202例，隨機分為治療組和對照組，兩組均給予常規治療；在此基礎上，治療組（101例）加用吡格列酮（15 mg/次，1次/天）治療，期間定期隨訪，1年後比較2組血液動脈粥樣硬化相關危險因素及心血管不良事件髮生率。結果治療組血清PAI-1（纖溶酶原激活物抑製物-1）水平為（4.15±0.47）ng/ml，P-選擇素水平為（12.38±3.56）ng/ml，對照組血清PAI-1水平為（7.46±1.73）ng/ml，P-選擇素水平為（15.84±6.32）ng/ml，兩組比較差異顯著（P＜0.05）；治療組空腹血糖、餐後血糖、空腹胰島素、糖化血紅蛋白水平和胰島素牴抗指數及急性冠脈綜閤徵、不穩定性心絞痛和靶血管重建髮生率顯著低于對照組，（P＜0.05）。結論吡格列酮用于治療2型糖尿病閤併冠心病，能降低其動脈粥樣硬化相關危險因素從而改善預後。
목적탐토필격렬동치료2형당뇨병합병관심병환자대기동맥죽양경화상관위험인소급예후적영향。방법선취2010년8월지2012년1월재본원진행치료적2형당뇨병합병관심병환자202례，수궤분위치료조화대조조，량조균급여상규치료；재차기출상，치료조（101례）가용필격렬동（15 mg/차，1차/천）치료，기간정기수방，1년후비교2조혈액동맥죽양경화상관위험인소급심혈관불량사건발생솔。결과치료조혈청PAI-1（섬용매원격활물억제물-1）수평위（4.15±0.47）ng/ml，P-선택소수평위（12.38±3.56）ng/ml，대조조혈청PAI-1수평위（7.46±1.73）ng/ml，P-선택소수평위（15.84±6.32）ng/ml，량조비교차이현저（P＜0.05）；치료조공복혈당、찬후혈당、공복이도소、당화혈홍단백수평화이도소저항지수급급성관맥종합정、불은정성심교통화파혈관중건발생솔현저저우대조조，（P＜0.05）。결론필격렬동용우치료2형당뇨병합병관심병，능강저기동맥죽양경화상관위험인소종이개선예후。
Objective To investigate the effects of atherosclerosis-related factors and prognosis of pioglitazone in the treatment of type 2 diabetes patients with coronary heart disease. Methods From August 2010 to January 2012, there were 202 patients in our hospital been treated for treatment of type 2 diabetes with coronary heart disease, and they were randomly divided into the treatment group(101cases) and the control group. The two groups were both given conventional treatment, and on this basis, the treatment group plus pioglitazone treatment(15 mg/d, qd). After 1 year regular follow-up period, compared the atherosclerosis risk factors and adverse cardiovascular events. Results In treatment group, the serum PAI-1 level was 4.15±0.47 ng/ml, P-selectin level was 12.38±3.56 ng/ml, in control group, the serum PAI-1 level was 7.46±1.73 ng/ml, P-selectin level was 15.84±6.32 ng/ml, significant difference(P<0.05);fasting blood glucose, postprandial glucose, fasting insulin, glycated hemoglobin levels and insulin resistance index and acute coronary syndrome, unstable angina pectoris Jinger target vessel revascularization in the treatment group were significantly lower than those in the control group(P<0.05). Conclusion Pioglitazone for the treatment of type 2 diabetes patients with coronary heart disease, which could reduce atherosclerosis risk factors and thus improve prognosis.
